Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises Stallergenes on its takeover by Waypoint

22 March 2019

Clifford Chance advises Stallergenes on its takeover by Waypoint

International law firm Clifford Chance is advising the Special Committee of Directors of biopharmaceuticals group Stallergenes Greer (EPA: STAGR) in relation to the recommended acquisition of the company by its controlling shareholder Waypoint. The transaction, announced today, values the company at approximately €730 million.

Waypoint currently owns approximately 84% of the company. Upon completion of the acquisition, which will be implemented through a scheme of arrangement, the company will be de-listed from Euronext Paris.

The Clifford Chance team is led by Corporate Partners Joel Ziff (London), Gilles Lebreton and Aline Cardin (both Paris).